Literature DB >> 28277310

Antipsychotic medication and remission of psychotic symptoms 10years after a first-episode psychosis.

Regitze Sølling Wils1, Ditte Resendal Gotfredsen2, Carsten Hjorthøj3, Stephen F Austin4, Nikolai Albert5, Rikke Gry Secher6, Anne Amalie Elgaard Thorup7, Ole Mors8, Merete Nordentoft9.   

Abstract

BACKGROUND: Several national guidelines recommend continuous use of antipsychotic medication after a psychotic episode in order to minimize the risk of relapse. However some studies have identified a subgroup of patients who obtain remission of psychotic symptoms while not being on antipsychotic medication for a period of time. This study investigated the long-term outcome and characteristics of patients in remission of psychotic symptoms with no use of antipsychotic medication at the 10-year follow-up.
METHODS: The study was a cohort study including 496 patients diagnosed with schizophrenia spectrum disorders (ICD 10: F20 and F22-29). Patients were included in the Danish OPUS Trial and followed up 10years after inclusion, where patient data was collected on socio-demographic factors, psychopathology, level of functioning and medication.
FINDINGS: 61% of the patients from the original cohort attended the 10-year follow up and 30% of these had remission of psychotic symptoms at the time of the 10-year follow up with no current use of antipsychotic medication. This outcome was associated with female gender, high GAF-F score, participation in the labour market and absence of substance abuse.
CONCLUSION: Our results describe a subgroup of patients who obtained remission while not being on antipsychotic medication at the 10-year follow-up. The finding calls for further investigation on a more individualized approach to long-term treatment with antipsychotic medication.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antipsychotic medication; First episode psychosis; Long-term outcome; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 28277310     DOI: 10.1016/j.schres.2016.10.030

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  21 in total

1.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

2.  Long-term antipsychotic treatment of schizophrenia: does it help or hurt over a 20-year period?

Authors:  Martin Harrow; Thomas H Jobe
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

3.  Early intervention services are effective and must be defended.

Authors:  Merete Nordentoft; Nikolai Albert
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

Review 4.  Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm.

Authors:  Chen-Chung Liu; Hiroyoshi Takeuchi
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

5.  A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia.

Authors:  Martin Harrow; Thomas H Jobe; Robert N Faull; Jie Yang
Journal:  Psychiatry Res       Date:  2017-06-22       Impact factor: 3.222

Review 6.  Potential drug targets and treatment of schizophrenia.

Authors:  Anil Kumar; Monu Yadav; Milind Parle; Sameer Dhingra; Dinesh K Dhull
Journal:  Inflammopharmacology       Date:  2017-03-28       Impact factor: 4.473

Review 7.  Does Gender Influence Outcome in Schizophrenia?

Authors:  Mary V Seeman
Journal:  Psychiatr Q       Date:  2019-03

8.  Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [18F]DOPA and [11C]raclopride PET study in first-episode psychosis.

Authors:  Seoyoung Kim; Sang Ho Shin; Barbara Santangelo; Mattia Veronese; Seung Kwan Kang; Jae Sung Lee; Gi Jeong Cheon; Woojoo Lee; Jun Soo Kwon; Oliver D Howes; Euitae Kim
Journal:  Mol Psychiatry       Date:  2020-09-14       Impact factor: 15.992

9.  Sex-Related Differences in White Matter Asymmetry and Its Implications for Verbal Working Memory in Psychosis High-Risk State.

Authors:  Saskia Steinmann; Amanda E Lyall; Mina Langhein; Felix L Nägele; Jonas Rauh; Suheyla Cetin-Karayumak; Fan Zhang; Marius Mussmann; Tashrif Billah; Nikos Makris; Ofer Pasternak; Lauren J O'Donnell; Yogesh Rathi; Marek Kubicki; Gregor Leicht; Martha E Shenton; Christoph Mulert
Journal:  Front Psychiatry       Date:  2021-06-14       Impact factor: 5.435

10.  Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data.

Authors:  Georgios Schoretsanitis; John M Kane; Christoph U Correll; Jose M Rubio
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 7.348

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.